Page last updated: 2024-12-06

plafibride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

plafibride: morpholino-methylurea analog of clofibric acid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68822
CHEMBL ID2107129
CHEBI ID135503
SCHEMBL ID309033
MeSH IDM0067214

Synonyms (36)

Synonym
67924-59-8
63394-05-8
2-[(4-chlorophenyl)oxy]-2-methyl-n-{[(morpholin-4-ylmethyl)amino]carbonyl}propanamide
propanamide, 2-(4-chlorophenoxy)-2-methyl-n-(((4-morpholinylmethyl)amino)carbonyl)-
plafibrida [inn-spanish]
ita 104
plafibrida [spanish]
einecs 264-121-2
n'-morpholinomethylurea, n-2-(p-chlorophenoxy)isobutyryl-
1-(2-(p-chlorophenoxy)-2-methylpropionyl)-3-(morpholinomethyl)urea
plafibridum [inn-latin]
n-2(p-chlorophenoxy)-2-methylpropionyl-n'-morpholinomethylurea
perifunal
n-2(p-chlorophenoxy)isobutyryl-n'-morpholinomethylurea
brn 0569805
idonor
plafibride [inn]
plafibride
ita-104
CHEBI:135503
2-(4-chlorophenoxy)-2-methyl-n-(morpholin-4-ylmethylcarbamoyl)propanamide
CHEMBL2107129
unii-5j7c4jz564
5j7c4jz564 ,
plafibridum
plafibrida
plafibride [mi]
plafibride [who-dd]
plafibride [mart.]
SCHEMBL309033
DTXSID1023491
ita 104; idonor; perifunal
Q27262403
CS-0026098
HY-106580
AKOS040749219

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with plafibride did not alter acute toxicity, which implies the absence of accumulation of the compound which would have led to an increase in toxicity."( Toxicological studies of plafibride. Part 1: Acute toxicity and its determination after several administrations of plafibride.
Bruseghini, L; Sanfeliu, C; Zapatero, J, 1981
)
0.89

Pharmacokinetics

ExcerptReferenceRelevance
" A mechanistic scheme for the degradation of plafibride is proposed, which agrees with the observed pharmacological and pharmacokinetic data."( Pharmacokinetic approach of plafibride in rat.
Bruseghini, L; Ribalta, JM; Torres, A; Vilageliu, J; Zapatero, D, 1981
)
0.82

Dosage Studied

ExcerptRelevanceReference
" The drug was administered at four dosage levels during induction of arteriosclerosis in order to establish a possible dose-effect relationship."( Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
Badimón, JJ; Cánovas, M; Padró, T; Vidal, M; Villaverde, CA, 1983
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]